Connor, Clark & Lunn Investment Management Ltd. Editas Medicine, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$4.67 - $7.28 $422,434 - $658,526	-90,457 Reduced 51.53%	85,098 $397,000
Q1 2024 May 09, 2024	BUY	$7.03 - $11.07 $1.13 Million - $1.78 Million	160,974 Added 1104.0%	175,555 $1.3 Million
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $91,131 - $161,994	14,581 New	14,581 $147,000
Q3 2022 Nov 10, 2022	BUY	$12.16 - $19.42 $48,980 - $78,223	4,028 Added 1.71%	240,244 $2.94 Million
Q2 2022 Aug 05, 2022	BUY	$9.99 - $21.35 $536,772 - $1.15 Million	53,731 Added 29.44%	236,216 $2.79 Million
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $1.53 Million - $3.01 Million	108,848 Added 147.82%	182,485 $3.47 Million
Q4 2021 Feb 10, 2022	SELL	$26.55 - $40.57 $1.26 Million - $1.92 Million	-47,448 Reduced 39.19%	73,637 $1.96 Million
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $572,085 - $1.06 Million	14,568 Added 13.68%	121,085 $4.97 Million
Q2 2021 Aug 12, 2021	BUY	$31.29 - $56.64 $1.49 Million - $2.69 Million	47,498 Added 80.48%	106,517 $6.03 Million
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $2.34 Million - $5.35 Million	59,019 New	59,019 $2.48 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$10.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$8.75 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$6.42 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$4.39 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$3.23 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account